Kindeva Drug Delivery announced that it will install a new MDI manufacturing line capable of filling either HFA-152a or HFO-1234ze, both of which have a lower global warming potential (GWP) than HFA 134a. The new line is expected to be in place by the end of 2022, and the company said that it plans to launch two MDIs formulated with the lower GWP propellants by … [Read more...] about Kindeva to install new MDI manufacturing line for filling lower GWP propellants
Products and Services
Strados Labs gets CE mark for RESP lung sounds sensor
Strados Labs announced that its RESP Smart Sensor Platform, which remotely measures and records lung sounds for use in respiratory disease treatment and clinical trials, has been granted a CE mark. According to Strados, a number of clinical trial sponsors are using measurements made by the RESP system as endpoints in studies of drugs in development for the treatment … [Read more...] about Strados Labs gets CE mark for RESP lung sounds sensor
TOA Pharmaceutical extends its agreement with Iconovo
According to DPI developer Iconovo, TOA Pharmaceutical has signed a new agreement for the use of an Iconovo dry powder inhaler for a feasibility study. TOA will pay €202,000 over the next year for use of the device in a development project for a generic aimed at the Japanese market. Iconovo did not specify which of its devices will be used in this new feasibility … [Read more...] about TOA Pharmaceutical extends its agreement with Iconovo
Akari Therapeutics chooses Inhalation Sciences for PK study of inhaled Nomacopan
According to Inhalation Sciences (ISAB), Akari Therapeutics has chosen ISAB's CRO, Inhalation Research Services, to conduct a pharmacokinetic study of Akari's Nomacopan, a C5 and LTB4 inhibitor that the company is evaluating as an inhaled therapy for the treatment of exacerbations in COPD and asthma. The PK study will be conducted using an isolated perfused lung (IPL) … [Read more...] about Akari Therapeutics chooses Inhalation Sciences for PK study of inhaled Nomacopan
Hovione to increase global capacity by 25%
CDMO Hovione said that it is investing $170 million to increase overall capacity at its manufacturing facilities in Portugal, Ireland, and the US by about 25% to meet strong demand. According to the company, its facilities expansion coincides with the addition of about 300 positions to its workforce. Hovione, which offers a full range of development and manufacturing … [Read more...] about Hovione to increase global capacity by 25%
Copley Scientific launches new nasal dose uniformity sampling apparatus interface
Inhaler testing equipment company Copley Scientific is introducing a new nasal dose uniformity sampling apparatus (DUSA) interface plate designed to work with the company's Vertus II/Plus shake and fire system for delivered dose uniformity testing of nasal products per Ph. Eur. 1 Chapter 0676 and USP Chapter <601>2. Earlier this year, the company announced the … [Read more...] about Copley Scientific launches new nasal dose uniformity sampling apparatus interface
Nemera launches UniSpray device for nasal delivery of systemic drugs
Device company Nemera has announced the launch of a new single metered dose nasal pump called UniSpray, which is designed for delivery of systemic drugs. According to the company, UniSpray requires no priming, is compatible with standard containers, and can be used at any angle. According to the announcement, UniSpray is a "concept under development," and the … [Read more...] about Nemera launches UniSpray device for nasal delivery of systemic drugs
Inhalation Sciences gets extension of XposeALI patent
According to Inhalation Sciences (ISAB), a US patent covering the XposeALI in vitro cell culturing module has been extended until 2034. US Patent No. 11054414 ("Exposure system") was originally filed in 2013, the company said. The patent is now expected to expire in 2034. The module, which works with the company's PreciseInhale dry powder aerosol testing system, … [Read more...] about Inhalation Sciences gets extension of XposeALI patent
Aptar Pharma to co-develop i2c’s Respitab MDI technology
Aptar Pharma will co-develop and promote i2c Pharmaceutical Services' Respitab MDI technology, the two companies have announced. The Respitab system involves formulating the drug as a tablet that can be easily dispensed into an MDI canister; the tablet is then dissolved or dispersed when the can is filled with propellant. According to the announcement, Aptar will … [Read more...] about Aptar Pharma to co-develop i2c’s Respitab MDI technology
Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis
Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec's mSAS supercritical fluid particle engineering technology. The first project for the two companies under the new agreement will be development of a dry powder formulation of teriparatide … [Read more...] about Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis